Abstract
Dermatomyositis is a heterogeneous syndrome with several associated antibodies, such as those against transcription intermediary factor 1-γ (anti–TIF-1γ), melanoma differentiation-associated gene 5 (anti–MDA-5), nuclear matrix protein 2 (anti–NXP-2), and small ubiquitin-like modifier–activating enzyme (anti-SAE). Each of these antibodies is referred to by neurologists and rheumatologists by its acronym for convenience,1 and each is associated with distinct clinical and histopathological features.2 More than 30 years ago, dermatomyositis was thought to be caused by complement-mediated microangiopathy, but there is evidence that the microvasculopathy and skin and muscle damage associated with dermatomyositis are due primarily to toxicity from pathways mediated by type I . . .

This publication has 9 references indexed in Scilit: